Search

Displaying results 3141 - 3150 of 10000 in total
  1. Drug

    Inotersen

    go.drugbank.com/drugs/DB14713
    ApprovedInvestigational

    Inotersen is a transthyretin-directed antisense oligonucleotide for the treatment of the polyneuropathy caused by hereditary transthyretin-mediated amyloidosis in adults. … Progressive amyloid accumulation may lead to multiorgan dysfunction and death [A39493].

  2. Drug

    p-tert-Butylphenol-formaldehyde resin (low molecular weight)

    go.drugbank.com/drugs/DB14190
    Approved

    Sensitivity to p-tert-Butylphenol-formaldehyde resin may be identified with a clinical patch test.

    Synonyms: p-tert-Butylphenol-formaldehyde resin (low molecular weight)
  3. Drug

    Chikungunya virus Senegal strain 37997 capsid protein

    go.drugbank.com/drugs/DB21766
    ApprovedInvestigational

    One of three components of a recombinant Chikungunya virus vaccine called Vimkunya.

  4. Drug

    Chikungunya virus Senegal strain 37997 envelope protein E2

    go.drugbank.com/drugs/DB21768
    ApprovedInvestigational

    One of three components of a recombinant Chikungunya virus vaccine called Vimkunya.

  5. Drug

    Eravacycline

    go.drugbank.com/drugs/DB12329
    ApprovedInvestigational

    It was first approved by the FDA on August 27, 2018 [L4540]. … Eravacycline, known as _Xerava_ by Tetraphase Pharmaceuticals, is a fully synthetic fluorocycline antibiotic of the tetracycline class with activity against clinically significant gram-negative, gram-positive

  6. Drug

    Nemolizumab

    go.drugbank.com/drugs/DB15252
    ApprovedInvestigational

    [A264254] By binding to IL-31RA, nemolizumab blocks the IL-31 signalling cascades that lead to inflammation. … [A264274] It was later approved by the FDA on August 13, 2024, for the treatment of prurigo nodularis.[L51169]

  7. Drug

    BHV-1300

    go.drugbank.com/drugs/DB22673
    Investigational

    BHV-1300 is a IgG1,2,4 selective degrader being investigated for the treatment of Grave's disease.

  8. Drug

    Emicizumab

    go.drugbank.com/drugs/DB13923
    ApprovedInvestigational

    [A31279, L1016] It was created by Chugai Pharmaceuticals Co. Ltd. and co-developed with Roche and Genentech.[L1015] … The ability of Emicizumab to bind to all these three different factors allows it to overcome immunogenicity and unstable hemostatic efficacy produced by previous Factor VII agents.

  9. Drug

    Esculin

    go.drugbank.com/drugs/DB13155
    Approved

    These are carbohydrate derivatives in which a sugar group is bonded through its anmoeric carbonA to another group via a C-, S-,N-,O-, or Se- glycosidic bond.

  10. Drug

    Dithiazanine

    go.drugbank.com/drugs/DB11516
    ApprovedVet approvedWithdrawn

    Dithiazanine iodide has been withdrawn from the market in countries such as France in Italy, but it may remain available in others.[A254427,L44032]